{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:41:02Z","timestamp":1772779262597,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple Myeloma (MM) predominantly affects older adults, with a median diagnosis age of 70 years, posing challenges in management due to frailty, comorbidities, and age-related physiological changes. As the aging population grows, the prevalence of MM in older patients is expected to rise, requiring improved clinical strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This consensus report outlines a multidisciplinary framework for the identification, geriatric assessment (GA), and management of older adults with MM, emphasizing the role of frailty assessments, such as the IMWG frailty score, in tailoring treatments. The objective is to develop a working model tailored to the Quebec context. A meeting on May 7, 2024 brought together experts to discuss improving access to GA and developing strategies for implementing geriatric management tools. Unmet needs include the lack of standardized screening tools, limited access to specialized geriatric oncology services, and inconsistent treatment approaches. Personalized care is critical in addressing frailty, comorbidities, patient preference, and functional status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This report proposes a structured referral pathway involving age-based triaging and criteria for geriatric consultation. Multidisciplinary teams, including geriatricians, are essential for optimizing care and improving outcomes, with a focus on quality of life and effective therapies. Standardized practices and collaborative approaches are vital for addressing the complexities of MM in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1632275","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:30:00Z","timestamp":1772775000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspective recommendations on geriatric support for older adults with multiple myeloma based on challenges faced by a multidisciplinary team"],"prefix":"10.3389","volume":"16","author":[{"given":"Julie","family":"C\u00f4t\u00e9","sequence":"first","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Universitaire (CHU) de Qu\u00e9bec \u2013 Universit\u00e9 Laval","place":["Quebec, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ploa","family":"Desforges","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University","place":["Montreal, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Dionne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services sociaux (CIUSSS) de la Capitale-Nationale","place":["QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Larose","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Laval","place":["Laval, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Martinez","sequence":"additional","affiliation":[{"name":"Direction de soins infirmiers, Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux (CIUSSS) du Centre-Ouest-de l\u2019\u00cele-de Montr\u00e9al","place":["Montr\u00e9al, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Trudel","sequence":"additional","affiliation":[{"name":"Department of Hematology, H\u00f4pital Charles-Le Moyne","place":["Greenfield Park, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drena","family":"Walker","sequence":"additional","affiliation":[{"name":"Hematology Pivot Nurse Cedars Cancer Center, McGill University Health Centre and RI-MUHC","place":["Montreal, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017635","article-title":"How I treat multiple myeloma in geriatric patients","volume":"143","author":"Facon","year":"2023","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.240095","article-title":"Projected estimates of cancer in Canada in 2024","volume":"196","author":"Brenner","year":"2024","journal-title":"CMAJ"},{"key":"B3","unstructured":"Statistiques du Registre Qu\u00e9b\u00e9cois du Cancer\n          \n          \n          \n          2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/hematology.2021000231","article-title":"Treatment of older adult or frail patients with multiple myeloma","volume":"2021","author":"Grant","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.028","article-title":"Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium","volume":"22","author":"LeBlanc","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.01.016","article-title":"First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium","volume":"23","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1061417","article-title":"Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews","volume":"12","author":"McKenzie","year":"2022","journal-title":"Front Oncol"},{"key":"B9","unstructured":"Steroid sparing treatment with in newly diagnosed transplant ineligible patients with multiple myeloma"},{"key":"B10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41408-023-00939-y","article-title":"MRD negativity: considerations for older adults with multiple myeloma","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"key":"B11","unstructured":"Multiple Myeloma"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.612696","article-title":"Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects","volume":"8","author":"Kaweme","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7500","article-title":"Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ)","volume":"42","author":"Facon","year":"2024","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02344-9","article-title":"OA-63 Daratumumab + Bortezomib\/Lenalidomide\/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study","volume":"24","author":"Usmani","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.02.019","article-title":"Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy","volume":"30","author":"Johnson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B22","unstructured":"Health canada approves the first and only anti-bcma car t cell therapy for multiple myeloma\n          \n          \n            \n              Myeloid\n              Canada"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01664-1","article-title":"MM-328 Efficacy and Safety of Teclistamab in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1\/2 MajesTEC-1 Study","volume":"24","author":"Luciano","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970424.05174.3c","article-title":"P880: Efficacy and safety of elranatamab by age and frailty in patients with relapsed\/refractory multiple myeloma (RRMM): a subgroup analysis from magnetismm-3","volume":"7","author":"Leleu","year":"2023","journal-title":"Hemasphere"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA105","article-title":"Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Trudel","year":"2024","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.36_suppl.439572","article-title":"Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Mateos","year":"2024","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28323","article-title":"Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant","volume":"119","author":"Jones","year":"2013","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113106","article-title":"Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients","volume":"12","author":"Bonello","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103657","article-title":"Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO\/SIOG Cancer in the Elderly Working Group","volume":"9","author":"Loh","year":"2024","journal-title":"ESMO Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgo.2016.04.001","article-title":"Management of multiple myeloma in older adults: Gaining ground with geriatric assessment","volume":"8","author":"Wildes","year":"2017","journal-title":"J geriatric Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00263","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Questions and Answers","volume":"19","author":"Williams","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2016.02.006","article-title":"Geriatric assessment in daily oncology practice for nurses and allied health care professionals: Opinion paper of the Nursing and Allied Health Interest Group of the International Society of Geriatric Oncology (SIOG)","volume":"7","author":"Burhenn","year":"2016","journal-title":"J geriatric Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-172X.2012.02017.x","article-title":"Nominal group technique: an effective method for obtaining group consensus","volume":"18","author":"Harvey","year":"2012","journal-title":"Int J Nurs Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1466366","article-title":"The Edmonton Frail Scale as a screening score for frailty in oncogeriatrics","volume":"11","author":"De Schrevel","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1771441","article-title":"Unmet Needs in Geriatric Oncology","volume":"12","author":"Pathi","year":"2023","journal-title":"South Asian J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31070279","article-title":"Improving Care for Older Adults with Cancer in Canada: A Call to Action","volume":"31","author":"Cook","year":"2024","journal-title":"Curr Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33658","article-title":"Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort","volume":"127","author":"Scheubeck","year":"2021","journal-title":"Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.14283\/jfa.2019.25","article-title":"Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review","volume":"8","author":"Mian","year":"2019","journal-title":"J Frailty Aging"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.171509","article-title":"Identification and management of frailty in the primary care setting","volume":"190","author":"Abbasi","year":"2018","journal-title":"CMAJ"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2009.01.004","article-title":"Treatment of relapsed\/refractory multiple myeloma","volume":"46","author":"Kastritis","year":"2009","journal-title":"Semin Hematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/08404704231182671","article-title":"Challenges and impacts from wait times for specialist care identified by primary care providers: Results from the MAAP study cross-sectional survey","volume":"36","author":"Marshall","year":"2023","journal-title":"Healthc Manage Forum"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/op.23.00263","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Questions and Answers","volume":"19","author":"Williams","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1632275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:30:02Z","timestamp":1772775002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1632275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":49,"alternative-id":["10.3389\/fonc.2026.1632275"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1632275","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"article-number":"1632275"}}